药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

未开盘 03-20 16:08:48

52.950

-1.250

-2.31%

最高55.400	最低52.100	成交量489.34万
今开54.350	昨收54.200	日振幅6.09%
总市值666.11亿	流通市值666.11亿	总股本12.58亿
成交额2.59亿	换手率0.39%	流通股本12.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":52.95,"timestamp":1773994128002,"preClose":54.2,"halted":0,"volume":4893374,"delay":0,"changeRate":-0.023062730627306273,"floatShares":1258000000,"shares":1258000000,"eps":0.829999,"marketStatus":"未开盘","change":-1.25,"latestTime":"03-20 16:08:48","open":54.35,"high":55.4,"low":52.1,"amount":259420318,"amplitude":0.060886,"askPrice":53,"askSize":202500,"bidPrice":52.95,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":1.118336,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":0,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":54.2,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":1.2411827717039103,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2620205448","title":"港股异动 | 东曜药业-B(01875)再涨超11% 年内股价已翻倍 药明合联收购要约正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620205448","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620205448?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:00","pubTimestamp":1773972047,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B再涨超11%，年内股价已实现翻倍，截至发稿，涨9.94%，报5.75港元，成交额2108.74万港元。消息面上，药明合联宣布，药明合联对东曜药业的现金要约收购已取得东曜药业60%股权之有效接纳，股份要约已正式生效。根据香港联交所披露的文件，3月17日，WuXi XDC Cayman Inc.以每股均价4.0港元场外增持东曜药业4.64亿股普通股股份，价值约18.55亿港元。增持后，其最新持股数目为4.64亿股股份，好仓比例由0.00%升至60.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"716700f540e2f30ce9084471cdfe18ec","theme_name":"热榜No.30 · 药明合联成功控股东曜药业，股价年内翻倍大涨","theme_type":2,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1574","02268","BK1141","SG9999014674.SGD","BK4588","BK4585","BK1161","LU2488822045.USD","01875"],"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620203185?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","02696","161726","BK1141","BK1147","IE00B543WZ88.USD","LU0348767384.USD","SG9999014674.SGD","LU2778985437.USD","BK4581","LU1969619763.USD","LU0561508036.HKD","LU2476274720.SGD","LU2476274308.USD","BK4585","HK0000306701.USD","06160","HK0000306685.HKD","LU2045819591.USD","LU0196878994.USD","LU0417516571.SGD","BK4588","399441","LU0348766576.USD","LU2125910500.SGD","09926","LU0348735423.USD","LU0307460666.USD","LU0348825331.USD","BK1588","HK0000320223.HKD","LU0588546209.SGD","BK1564","02359","601881","LU0708995583.HKD","06990","09995","LU1720050803.USD","BK1161","LU2328871848.SGD","LU0052750758.USD","BK0276","LU0540923850.HKD","LU2242644610.SGD","06881","LU1770034418.SGD","XBI","02268"],"gpt_icon":0},{"id":"2620292008","title":"港股异动 | 东曜药业-B(01875)涨超9% 药明合联已取得公司60%股权有效接纳 收购要约正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292008","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620292008?lang=zh_cn&edition=full","pubTime":"2026-03-19 09:57","pubTimestamp":1773885457,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B涨超9%，截至发稿，涨8.02%，报4.85港元，成交额1989.09万港元。消息面上，3月18日，药明合联宣布，公司已成功获得东曜药业60%股权之有效接纳，本次收购要约已正式生效。据药明合联介绍，本次收购要约的最后可接纳截止日期为2026年3月31日下午4时，东曜药业股东将在剩余的时间里决策是否接纳本次要约。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02268","BK4585","01875","BK4588","BK1141","BK1161","VXUS","LU2488822045.USD","SG9999014674.SGD"],"gpt_icon":0},{"id":"2620449190","title":"港股异动 | 东曜药业-B(01875)午后涨超5% 药明合联收购条件到期未达成 要约期已延长","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449190","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620449190?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:23","pubTimestamp":1773732198,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B(01875)午后涨超5%，截至发稿，涨4.04%，报43.8港元，成交额815.65万港元。消息面上，今年1月，东曜药业获药明合联溢价约99%提现金要约。据悉，本次收购成功的关键在于药明合联能否在截止日期前获得至少60%的东曜药业投票权。药明合联此前已经锁定了持有42.16%股份的五大主要股东的“不可撤销承诺”。3月13日，公司公告称，由于接纳条件于首个截止日期未获达成，要约人把首个截止日期延长至2026年3月27日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","LU2488822045.USD","BK1141","BK1574","SG9999014674.SGD","02268","VXUS","BK4585","01875"],"gpt_icon":0},{"id":"2620449806","title":"招银国际：料中国医疗行业基本面加速向好 推荐买信达生物(01801)三生制药(01530)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620449806?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:07","pubTimestamp":1773731228,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨0.6%，跑赢MSCI中国指数3.5%。医药行业近期明显回调，特别是创新药板块回调幅度较大。同时，AI制药技术突破与中国创新药踏出海外BD的爆发形成双重共振，该行预计行业基本面加速向好。该行表示，推荐买入信达生物、三生制药、加科思、固生堂 、药明合联，目标价分别110.62港元、37.43港元、10.34港元、44.95港元及88港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d0f3c5bccb622a532fbc5668691928ff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1219","SG9999014674.SGD","LU1969619763.USD","LU2488822045.USD","159891","02268","LU2097828631.EUR","LU2097828805.USD","01167","LU0455707207.USD","LU2242644610.SGD","LU2097828557.USD","BK1161","01801","LU0502904849.HKD","01530","LU2328871848.SGD","HK0000165453.HKD","BK1574","BK1141","LU2097828714.EUR","BK1583","BK1589","02273","BK1593","LU2097828474.EUR"],"gpt_icon":0},{"id":"1150046369","title":"港股生物医药概念股走高，药明合联涨近7%，荣昌生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150046369","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150046369?lang=zh_cn&edition=full","pubTime":"2026-03-17 10:28","pubTimestamp":1773714505,"startTime":"0","endTime":"0","summary":"3月17日，$生物(000504)$医药概念股走高，$药明合联(02268)$涨近7%，$荣昌生物(09995)$涨超5%，$君实生物(01877)$、$诺诚健华(09969)$、$药明康德(02359)$等个股跟涨","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5f115a7e903cc298acc05fac997c6569","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4581","LU2148510915.USD","02268","LU2328871848.SGD","LU2488822045.USD","SG9999014674.SGD","LU1064130708.USD","BK1161","BK1574","LU1969619763.USD","LU1064131003.USD","BK0239","09995","BK4585","BK4588","BK1141"],"gpt_icon":0},{"id":"1154028533","title":"药明合联（02268）收购东曜药业（01875）首轮接纳达46.54%，要约延至3月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=1154028533","media":"公告速递","labels":["shareholding","merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154028533?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:36","pubTimestamp":1773398177,"startTime":"0","endTime":"0","summary":"药明合联生物技术有限公司与东曜药业股份有限公司3月13日晚联合公告，药明合联透过花旗环球金融亚洲有限公司作出的自愿有条件现金要约，于首个截止日期已收到对3.5963亿股东曜药业股份的有效接纳，占东曜药业已发行股本及表决权约46.54%。同时，购股权要约方面，共有651.26万份购股权被有效接纳，占东曜药业尚未行使购股权总额约85.33%。药明合联已将截止日期延长14日至3月27日16:00，其余条款维持不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"gpt_icon":0},{"id":"2618980010","title":"每日卖空追踪 | 药明合联 03月10日卖空量成交41万股，卖空比例为12.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980010","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618980010?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131429,"startTime":"0","endTime":"0","summary":"药明合联北京时间03月10日，涨2.52%，卖空量成交41万股，较上一交易日减少45.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163351a6b4d5d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163351a6b4d5d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","LU2488822045.USD","02268","SG9999014674.SGD"],"gpt_icon":0},{"id":"2618980065","title":"药明合联03月10日主力净流入191.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980065","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618980065?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:15","pubTimestamp":1773130546,"startTime":"0","endTime":"0","summary":"03月10日, 药明合联股价涨2.52%，报收59.00元，成交金额1.9亿元，换手率0.26%，振幅3.56%，量比0.63。药明合联今日主力资金净流入191.4万元，上一交易日主力净流出296.3万元。该股近5个交易日下跌0.34%，主力资金累计净流入2385.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1872.7万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161918a6b4c81c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161918a6b4c81c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2617865322","title":"每日卖空追踪 | 药明合联 03月06日卖空量成交43.7万股，卖空比例为12.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617865322","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617865322?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:30","pubTimestamp":1772785828,"startTime":"0","endTime":"0","summary":"药明合联北京时间03月06日，涨3.3%，卖空量成交43.7万股，较上一交易日减少74.28%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163343a4535b89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163343a4535b89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","BK1141","02268","LU2488822045.USD"],"gpt_icon":0},{"id":"2617919503","title":"【券商聚焦】交银国际：医药公司业绩兑现有望催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2617919503","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617919503?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:08","pubTimestamp":1772759313,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，2026年以来，内资通过港股通持有医药股的比例呈现先降后升态势，当前水平与年初持平，外资持仓则有所提升。本周内资继续加仓创新药产业链和器械标的，外资则重点布局创新药企及CXO企业。年报季临近，本周各公司业绩预告陆续发布，该机构建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU2476274720.SGD","SG9999014674.SGD","02268","LU1961090484.USD","09688","BK1585","SG9999004311.SGD","02196","LU2488822045.USD","LU2399975544.HKD","BK1593","BK1141","LU0588546209.SGD","02228","BK1207","LU0640798160.USD","LU1115378108.SGD","BK1191","LU0417516571.SGD","02367","LU2476274308.USD","03933","LU1770034418.SGD","03329","01789","BK1574","LU0561508036.HKD","LU2778985437.USD","09939","BK1197","LU0348766576.USD","LU1719994722.HKD","159938","LU0348825331.USD","09926","LU1794554557.SGD","01099","BK1515","LU0348783233.USD","LU0348784397.USD","LU0348827113.USD","LU0348735423.USD","LU0540923850.HKD","LU1303224171.USD","LU2328871848.SGD","06160","01530","HK0000165453.HKD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"1193876028","title":"药明合联（02268）2026年2月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193876028","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193876028?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:19","pubTimestamp":1772702347,"startTime":"0","endTime":"0","summary":"WuXi XDC Cayman Inc.于2026年3月5日披露2026年2月股份变动月报表。公告显示，截至2026年2月底，公司股本结构整体保持稳定，未有新增发行或回购活动。已发行股份总数维持在1,257,992,705股，库藏股份数量为0，未发生变动。此外，公司于2024年股份计划下已批准授出尚未发行的普通股累计10,285,226股，本月同样无变动。公司声明已遵守香港联交所《主板上市规则》及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7babad1b4c042890cc8c6c387e110b44","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"gpt_icon":0},{"id":"2617308590","title":"每日卖空追踪 | 药明合联 03月04日卖空量成交62.85万股，卖空比例为6.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617308590","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617308590?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613028,"startTime":"0","endTime":"0","summary":"药明合联北京时间03月04日，跌5.41%，卖空量成交62.85万股，较上一交易日减少41.7%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163411a44a6e16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163411a44a6e16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","SG9999014674.SGD","02268","LU2488822045.USD"],"gpt_icon":0},{"id":"2616306232","title":"大摩：药明合联(02268)股价未来30日将绝对上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2616306232","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616306232?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:27","pubTimestamp":1772530053,"startTime":"0","endTime":"0","summary":"该行给予药明合联目标价为86港元，其评级为“增持”。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260303/20260303172831_42715.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260303/20260303172831_42715.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2488822045.USD","BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2616279318","title":"交银国际维持药明合联“买入”评级，受益于行业景气度稳步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2616279318","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616279318?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:40","pubTimestamp":1772444440,"startTime":"0","endTime":"0","summary":"相关公司：交银国际hk03329本文转载自乐居财经，转载目的在于传递更多信息，并不代表本站赞同其观点和对其真实性负责。本站拥有对此声明的最终解释权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302174755a731191c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302174755a731191c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268"],"gpt_icon":0},{"id":"2616318201","title":"每日卖空追踪 | 药明合联 03月02日卖空量成交30.3万股，卖空比例为6.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616318201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616318201?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:30","pubTimestamp":1772440232,"startTime":"0","endTime":"0","summary":"药明合联北京时间03月02日，跌2.77%，卖空量成交30.3万股，较上一交易日减少69.64%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163437a730c74d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163437a730c74d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","02268","SG9999014674.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"2616538865","title":"【券商聚焦】招银国际：AI将改变创新药物研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2616538865","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616538865?lang=zh_cn&edition=full","pubTime":"2026-03-02 14:40","pubTimestamp":1772433633,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，MSCI中国医疗指数2026年初至今累计上涨5.0%，跑赢MSCI中国指数6.2%。医药行业近期明显回调（MSCI中国医疗指数1月15日至今累计下跌9%），特别是创新药板块回调幅度较大（恒生生物科技指数1月15日至今累计下跌13%）。该机构认为，此轮调整原因包括博弈层面行业短期缺乏催化剂，以及行业轮动导致资金流出医药板块。中国创新药资产出海BD持续超预期，MNC对于中国资产的购买范围从单个管线拓宽至平台合作，进一步体现了中国创新药的竞争力。该机构认为，中国的AI制药技术发展迅猛，将涌现一批优秀的创新企业。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1975709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","BK1161","IE00B543WZ88.USD","06978","BK1585","LU0348783233.USD","01099","LU0307460666.USD","02367","LU0348784397.USD","HK0000165453.HKD","02196","LU1961090484.USD","SG9999014674.SGD","LU1969619763.USD","LU1720050803.USD","BK1141","03933","02268","BK1617","09926","159992","BK1100","BK1197","LU2328871848.SGD","LU2488822045.USD","LU2476274720.SGD","SG9999004311.SGD","IE00B5MMRT66.SGD","LU0588546209.SGD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0640798160.USD","06160","LU0348827113.USD","02228","09688","LU1251922891.USD","BK1207","BK1574","LU1303224171.USD","LU0561508036.HKD","01530","LU1794554557.SGD","01789","LU1115378108.SGD","BK1515","BK1583","LU0348735423.USD","LU0348825331.USD"],"gpt_icon":0},{"id":"2616500807","title":"大行评级丨大摩：相信药明合联股价在未来30日将绝对上涨，目标价86港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616500807","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616500807?lang=zh_cn&edition=full","pubTime":"2026-03-02 13:37","pubTimestamp":1772429823,"startTime":"0","endTime":"0","summary":"摩根士丹利发表技术意见报告，相信药明合联股价在未来30日将绝对上涨，主要是该股近期交易价格下跌，令短期估值更具吸引力。药明康德宣布一项涉及其有效载荷连接子技术平台的规模可观的对外授权协议。此类协议包括预付款、里程碑付款以及潜在的销售分成，这些都将有助于提升销售额和盈利能力。该行给予药明合联目标价为86港元，评级“增持”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260302/32037238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02268"],"gpt_icon":0},{"id":"1193991119","title":"药明合联与Earendil Labs就Wuxitecan-2有效载荷-连接子技术平台达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1193991119","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193991119?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:14","pubTimestamp":1772183652,"startTime":"0","endTime":"0","summary":"药明合联（WuXi XDC）宣布与Earendil Labs建立战略合作伙伴关系，双方将围绕Wuxitecan-2有效载荷-连接子技术平台展开深度协作。此次合作旨在整合彼此在生物偶联技术领域的优势资源，共同推进新型抗体偶联药物（ADC）技术的开发与应用。\n通过本次战略联手，药明合联将借助Earendil Labs在创新有效载荷-连接子技术方面的专长，进一步拓展其ADC技术平台的能力边界。Wuxitecan-2作为新一代拓扑异构酶I抑制剂有效载荷，具有显著的治疗潜力，这项合作将加速其在癌症治疗领域的创新应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SG9999014674.SGD","02268","BK1141"],"gpt_icon":0},{"id":"2614045007","title":"药明合联午前涨近8% 公司有望持续受益XDC CRDMO行业下游需求改善趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045007","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614045007?lang=zh_cn&edition=full","pubTime":"2026-02-27 11:55","pubTimestamp":1772164500,"startTime":"0","endTime":"0","summary":"　　药明合联盘中涨超8%，截至发稿，股价上涨7.54%，现报62.75港元，成交额3.01亿港元。2024年年初以来，XDC领域投融资事件数、BD交易数和首付款总额呈逐步上升态势。投融资和BD交易持续活跃，将进一步拉动XDC CRDMO行业下游需求改善，药明合联作为技术实力和一体化交付能力布局的龙头企业，有望持续受益于这一重要趋势、并扩大市场份额。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-27/doc-inhpfnzn6798937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","SG9999014674.SGD","BK1141","02268"],"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.0213},{"period":"1month","weight":-0.1854},{"period":"3month","weight":-0.2436},{"period":"6month","weight":-0.2479},{"period":"1year","weight":0.1536},{"period":"ytd","weight":-0.1284}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0535},{"period":"3month","weight":-0.0161},{"period":"6month","weight":-0.0478},{"period":"1year","weight":0.0437},{"period":"ytd","weight":-0.0138}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}